NCT00002663 2023-02-13Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or MalignanciesAtara BiotherapeuticsPhase 1/2 Completed58 enrolled 18 charts
NCT01748721 2016-01-08MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or LymphomaMorphotekPhase 1 Completed27 enrolled
NCT00099255 2014-12-18Study of SGN-30 (Anti-CD30 mAb) in Patients With Primary Cutaneous Anaplastic Large Cell LymphomaSeagen Inc.Phase 2 Completed40 enrolled
NCT00051597 2011-10-12A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic MalignanciesSeagen Inc.Phase 1/2 Completed70 enrolled
NCT00298467 2010-04-26MDX-060 in Patients With Relapsed or Refractory Classic Systemic or Primary Cutaneous Anaplastic Large Cell LymphomaBristol-Myers SquibbPhase 2 Withdrawn45 enrolled